1439205-35-2Relevant articles and documents
Discovery of TAK-960: An orally available small molecule inhibitor of polo-like kinase 1 (PLK1)
Nie, Zhe,Feher, Victoria,Natala, Srinivasa,McBride, Christopher,Kiryanov, Andre,Jones, Benjamin,Lam, Betty,Liu, Yan,Kaldor, Stephen,Stafford, Jeffrey,Hikami, Kouki,Uchiyama, Noriko,Kawamoto, Tomohiro,Hikichi, Yuichi,Matsumoto, Shin-Ichi,Amano, Nobuyuki,Zhang, Lilly,Hosfield, David,Skene, Robert,Zou, Hua,Cao, Xiaodong,Ichikawa, Takashi
, p. 3662 - 3666 (2013/07/05)
Using structure-based drug design, we identified and optimized a novel series of pyrimidodiazepinone PLK1 inhibitors resulting in the selection of the development candidate TAK-960. TAK-960 is currently undergoing Phase I evaluation in adult patients with